Reduced-Dose Apixaban and Rivaroxaban Versus Low-Molecular-Weight Heparin in Patients With Hematologic Malignancies | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Reduced-Dose Apixaban and Rivaroxaban Versus Low-Molecular-Weight Heparin in Patients With Hematologic Malignancies	Blood Protein Disorders, Embolism, Embolism and Thrombosis, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Thromboembolism, cardiovascular disorder, hematologic disorder, hematopoietic and lymphoid system neoplasm, hemorrhagic disease, immune system disorder, immunoproliferative disorder, leukemia, lung disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell neoplasm, pulmonary embolism, respiratory system disorder, vascular disorder, vascular hemostatic disease, venous thromboembolism	Recruiting	Not applicable	2025-12-26		NCT07270263

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Medical University of Gdansk	56

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Department of Haematology & Transplantology	Gdansk	Poland	1